Full-Time
$440k - $550k/yr
Senior, Expert
H1B Sponsorship Available
Pasadena, CA, USA
Relocation Assistance available; candidates from California, Nevada, Arizona, Oregon, and Florida are encouraged to apply.
Upload your resume to see how it matches keywords from the job description.
Company Size
201-500
Company Stage
IPO
Headquarters
Cerritos, California
Founded
2007
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Hybrid Work Options
CERRITOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today proudly announced the launch of the Florida Oncology Network. This new fully delegated network will expand access to high-quality, coordinated cancer care for Florida residents.The Florida Oncology Network includes TOI Clinics and a robust panel of value-focused medical and radiation oncologists strategically located throughout the state. The network is designed to provide comprehensive cancer care that is accessible, affordable, and focused on outcomes for patients and payor partners.Under the delegated arrangement, TOI has partnered with Provider Network Solutions (PNS), the market leader in specialty MSO and third-party administrative services, and through its affiliates will provide claims administration and processing as well as network management. The collaboration brings together TOI’s nationally recognized clinical model and PNS’s deep experience supporting delegated provider networks in Florida. Together, the organizations will focus on improving patient outcomes, reducing unnecessary variation in care, and aligning incentives with value-based objectives.The Florida Oncology Network commences operations effective immediately, with plans to grow both its geographic footprint and patient reach across Florida throughout 2025
The Oncology Institute (NASDAQ: TOI) has secured a $16.5 million private placement from accredited investors, including existing investors, management, and Board Directors, expected to close on March 26, 2025. The placement involves units priced at $2.2084, consisting of two common stock shares and warrants. Deerfield Management will exchange $4.1 million of TOI's convertible notes for preferred shares and warrants. Proceeds will support organic growth and working capital needs.
Toi Management, LLCCERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOI’s success as a public company.Mr. Castle joins TOI with over 15 years of oncology industry experience, and has a track record of driving growth and profitability for multi-state physician groups
SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI) and House Rx announced today that they have entered into a multi-year relationship that will integrate House Rx’s specialty medication dispensing model to operate and manage TOI’s clinic and pharmacy locations in multiple markets.House Rx provides clinics with specialized technology and services support from pharmacists and care coordinators. House Rx staff are integrated with the clinic to help patients start therapy as quickly as possible and drive adherence to treatment for better outcomes.TOI’s alignment with House Rx will expand patient access to oral specialty medications via TOI dispensary and pharmacy locations, and enhance in-office dispensary operations. The relationship will further enable TOI to provide convenient and affordable access to value-based therapies for patients as part of its comprehensive community-based care model.“By partnering with House Rx, we will accelerate the growth of our clinic-based oral drug dispensing capabilities and improve our ability to add pharmacy locations in California and Texas that will allow us to access patient populations that we previously could not serve,” said Dr. Daniel Virnich, CEO of The Oncology Institute. “We see this as one of the key drivers of our growth in upcoming years.”"With TOI, we have an innovative partner that cares deeply about delivering value-based care in the community setting," said Tesh Khullar, President and Co-Founder of House Rx. "By adopting our dispensing services and technology, TOI will strengthen their value-based care offering by ensuring more patients can access their specialty medications and receive the best possible outcomes from their treatments.”About The Oncology Institute, Inc.Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting
CERRITOS, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), has announced a strategic acquisition that aims to further consolidate the Greater Los Angeles market and establish the company as one of the largest value-based community oncology groups in the United States. The acquisition of Southland Radiation Oncology Network (SRON) will amplify TOI's radiation oncology market presence by five additional clinics across the eastern San Gabriel Valley and Inland Empire, providing TOI with a distinct advantage over local private practices and tertiary centers. The acquisition of SRON is an important milestone for TOI as they continue to expand their ability to provide complete population health for oncology care. It will enable broader coverage across the Los Angeles area, providing more access to life-saving care for those who may not be able to otherwise afford treatment or transportation. "We are thrilled to be taking this next step in our journey as we expand our radiation oncology practice locations, and look forward to serving the community with the highest quality of care," said Dan Virnich, MD, MBA, FACHE, President of The Oncology Institute. "This acquisition aligns with our strategic vision to be the leading value-based cancer care group in the U.S., and demonstrates our commitment to delivering comprehensive oncology solutions that will benefit our patients and the broader community." The acquisition of SRON will enable TOI to offer value-based radiation oncology care to more patients in the Greater Los Angeles area